NCT07233512Enrolling by invitation
EFFECT OF PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES
EFFECT OF SURGICAL AND NON-SURGICAL PERIODONTAL TREATMENT ON ALZHEIMER DISEASE-ASSOCIATED OUTCOMES: A Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
Periodontitis is the most prevalent chronic infectious inflammatory disease in adults, leading to the destruction of tooth-supporting tissues. Beyond its local impact, periodontitis contributes to systemic inflammation through the release of periodontal pathogens and their byproducts into the bloodstream. Given that chronic intracerebral inflammation is a known driver of Alzheimer's disease (AD) progression, a biological link between the two conditions has been hypothesized. This study aims to evaluate whether periodontal treatment can influence AD progression by reducing systemic inflammation. We have designed a randomized controlled clinical trial including 70 patients diagnosed with both AD and stage 3 or 4 periodontitis, randomly allocated to receive either immediate (test group) or delayed (control group) periodontal therapy. All participants will undergo comprehensive periodontal treatment and be followed over a 24-month period. Cognitive assessments, periodontal evaluations, blood and saliva biomarker analyses, and neuroimaging will be conducted at multiple time points to assess the potential impact of periodontal therapy on AD progression. This trial represents the first clinical investigation into the effect of periodontal treatment on the course of Alzheimer's disease.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 17 Nov 2023
- Primary completion date
- 10 Sept 2029
- Lead sponsor
- Centre Hospitalier Universitaire de Liege
- Diseases
- Alzheimer disease
- NCT number
- NCT07233512
What you commit to
- Study type: Interventional
- Planned participants: 26
- From 17 Nov 2023 to the primary completion date, 10 Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressive drugs or chemotherapy
Other
- Participation in another clinical trial (30 days)
- Contra-indication for MRI
- Use of antibiotics in the past 3 months
Who the study is looking for
- Have to suffer from AD
- Must agree to have brain imaging (without contra-indication for MRI)
- Possess a minimum of 10 residual teeth
- Have an MMSE score greater than 15
- Exhibit a DPSI score of ≥ 3+ indicating advanced periodontal disease
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Liège, Université de Liège Domaine du Sart Tilman Coordinator of this site? Confirm its status | Liège | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.